Drugdu.com expert's response:

When doing foreign trade in pharmaceuticals and medical devices, some inquiries may seem very appealing at first glance. The buyer hasn’t asked many detailed product questions, and hasn’t even clarified samples, prices or documents, but they will immediately put forward a request: “Can we be your exclusive distributor?” or “We want to be your exclusive agent in our market.”

For suppliers, this type of information can easily arouse expectations. Compared with ordinary price inquiries, exclusive agency sounds more like long-term cooperation, and more like the channel resources that enterprises truly want when expanding overseas. Especially for enterprises that are developing overseas markets, they are already eager to find local agents, distributors or long-term partners. When they see buyers taking the initiative to propose exclusive agency, they will naturally list this lead as a top priority.

However, bringing up exclusive agency right at the very beginning does not necessarily mean that the buyer has mature channels, nor does it indicate that the project has reached the stage where an agency agreement can be signed. Some buyers are indeed local distributors who are searching for new product lines; some just want to learn about the supplier’s cooperation policies first; there are also some companies that will request authorization from multiple manufacturers at the same time, hoping to secure the agency identity first before slowly finding clients and orders.

Therefore, exclusive agency can be discussed, but it is not suitable to agree to it immediately.

When a buyer proposes exclusive agency, the first thing the supplier needs to assess is not how enthusiastic the other party speaks, but whether they have the ability to successfully promote this product in the local market. For example, what products are they currently operating, whether they have sales experience in similar products, who their main clients are, which channels they cover, and whether they have previous experience in product registration, bidding, hospital access or distribution network construction.

For medical devices, it is also necessary to check whether the other party understands the local registration requirements, whether they have access to hospitals, clinics, distributors or government procurement channels, and whether they can undertake after-sales service, training, spare parts supply, labeling and localized documentation work. For pharmaceuticals, APIs, excipients and other pharmaceutical products, it is also important to confirm whether the buyer is an importer, distributor, end pharmaceutical manufacturer, or just an intermediate trader. Different identities correspond to completely different cooperation values and risks.

The part that is most prone to ambiguity in exclusive agency discussions is the territory and product scope. When a buyer says “we want to be your exclusive agent in our country”, it sounds very clear, but many problems will arise during actual implementation. Is the exclusivity for the entire country, or for a specific region? Is it exclusive for the full product line, or for only several selected products? Does it cover online channels, hospital channels, retail channels, or project procurement channels? If these boundaries are not clarified in advance, channel conflicts are very likely to occur later.

Some distributors only cover a certain type of clients, yet they hope to obtain national exclusive rights; some clients are only interested in one or two products, but they want to bind the enterprise’s entire product line; there are also some buyers who have not completed their first purchase, but demand that the supplier stop contacting other local clients. If the supplier agrees too early, the subsequent market may end up being locked in a disadvantageous situation.

For first-time cooperating buyers, a more prudent approach is to place exclusive agency in the subsequent cooperation stage for discussion, rather than making a commitment in the first round. Suppliers can go through samples, document review, trial orders, registration assessment or small-batch purchases first, to verify whether the other party truly has the ability to move the project forward. Whether a client can become a long-term agent depends not only on how proactive they are in the early stage, but also on whether they provide timely feedback, can offer market information, are willing to invest in registration and promotion, and can deliver actual orders.

When negotiating agency rights, do not only focus on the sales volume promised by the buyer. Many clients will claim that the local market is huge and they can sell a certain quantity in the coming year, but these figures can only serve as references if they are not supported by channels, clients, registration and promotion plans. What truly deserves attention is: whether they currently have relevant client resources, have sold similar products before, are familiar with the local access procedures, are willing to make market investments, and can provide phased procurement plans.

If you do need to enter into exclusive agency discussions, the supplier must clarify at least several key conditions: agency territory, product scope, cooperation term, minimum purchase volume, annual targets, pricing policy, payment terms, registration responsibilities, market promotion responsibilities, after-sales responsibilities, and the handling mechanism when the agreed targets are not met. Especially for medical devices and pharmaceutical products that involve local registration, it is also necessary to confirm in advance who will hold the registration certificate or license, which documents the supplier will provide, and how the registration materials and authorization will be handled after the cooperation terminates.

If such issues are not clarified in the early stage, the subsequent problems may be more troublesome than those of ordinary orders. Because once exclusivity is involved, the supplier is not just selling products, but also entrusting the other party with the development of a certain market, a specific channel or a certain type of clients. If the other party lacks sufficient capabilities, what the supplier loses is not just this single order, but also the opportunity to develop other clients for a period of time.

Of course, the fact that buyers are not suitable to be granted exclusive agency immediately does not mean that this inquiry has no value. Some clients cannot meet the conditions for national exclusive agency for the time being, but they can start with ordinary distribution, regional cooperation, single-product agency or non-exclusive cooperation. Completing one purchase first and then observing their response speed, payment performance, market information and repurchase capability is much more stable than signing a long-term exclusive agreement right at the start.

When an overseas buyer brings up exclusive agency right at the very beginning, it shows that they are interested in the cooperation model, and it may also indicate that this lead is more than just an ordinary purchase. But suppliers should not only be attracted by the words “exclusive distributor”. What really matters is whether this buyer has established channels, clear plans, execution capabilities, and can gradually implement the registration, documentation, procurement and market promotion work step by step.

For suppliers, exclusive agency is not something that cannot be discussed. Instead, it should be negotiated only after the information is sufficiently clear, the cooperation has a solid foundation, and the responsibilities of both parties can be clearly specified. In the first round of communication, you can actively learn about their situation, and keep room for subsequent cooperation, but do not rush to hand over an entire market to them.